Please login to the form below

Not currently logged in
Email:
Password:

Erleada

This page shows the latest Erleada news and features for those working in and with pharma, biotech and healthcare.

J&J puts pressure on rivals with new Erleada okay in prostate cancer

J&J puts pressure on rivals with new Erleada okay in prostate cancer

and Pfizer’s drug as it tries to position Erleada as a successor to Zytiga. ... The study found that Erleada reduced the risk of death by 33% compared to the control group.

Latest news

More from news
Approximately 3 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Erleada (apalutamide) is the first drug to be cleared on the strength of metastasis-free survival (MFS), a trial endpoint not used before in any FDA cancer drug approval. ... The median MFS for patients taking Erleada was 40.5 months compared to 16.2

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Five key trends in precision and personalised healthcare
Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...

Infographics